Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
ALDX on Nasdaq
Shares outstanding
59,794,743
Price per share
$5.54
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
38,929,706
Total reported value
$201,592,852
% of total 13F portfolios
0%
Share change
-531,713
Value change
-$2,790,250
Number of holders
134
Price from insider filings
$5.54
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PERCEPTIVE ADVISORS LLC 7% -19% $17,286,660 -$4,281,484 4,185,632 -20% Perceptive Advisors LLC 31 Dec 2025

As of 31 Dec 2025, 134 institutional investors reported holding 38,929,706 shares of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX). This represents 65% of the company’s total 59,794,743 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Knoll Capital Management, LLC 9.2% 5,475,516 0% 13% $28,363,172
PERCEPTIVE ADVISORS LLC 7% 4,185,632 -20% 0.4% $21,681,574
BlackRock, Inc. 6.4% 3,850,103 +1.2% 0% $19,943,533
VANGUARD GROUP INC 6.2% 3,698,682 +3% 0% $19,159,173
KINGDON CAPITAL MANAGEMENT, L.L.C. 3.1% 1,850,000 +39% 1.5% $9,583,000
D. E. Shaw & Co., Inc. 2.7% 1,601,324 +16% 0.01% $8,294,858
683 Capital Management, LLC 2.6% 1,530,000 +87% 0.66% $7,925,400
ARDSLEY ADVISORY PARTNERS LP 2.4% 1,450,000 -24% 0.96% $7,511,000
KENNEDY CAPITAL MANAGEMENT LLC 2.1% 1,255,838 +13% 0.14% $6,505,241
AQR CAPITAL MANAGEMENT LLC 2.1% 1,226,922 -18% 0% $6,355,456
GEODE CAPITAL MANAGEMENT, LLC 2% 1,170,537 -0.5% 0% $6,064,616
STATE STREET CORP 1.8% 1,098,600 -0.37% 0% $5,690,748
ACADIAN ASSET MANAGEMENT LLC 1.6% 979,521 +17% 0.01% $5,071,000
JACOBS LEVY EQUITY MANAGEMENT, INC 1.6% 968,751 +2.2% 0.02% $5,018,130
MORGAN STANLEY 1.1% 657,032 -39% 0% $3,403,426
DIMENSIONAL FUND ADVISORS LP 1% 612,258 -5.6% 0% $3,171,391
BANK OF AMERICA CORP /DE/ 0.69% 410,028 +5.1% 0% $2,123,946
NORTHERN TRUST CORP 0.63% 379,405 -7% 0% $1,965,318
WELLS FARGO & COMPANY/MN 0.61% 366,169 +1.3% 0% $1,896,755
RENAISSANCE TECHNOLOGIES LLC 0.59% 350,000 +77% 0% $1,813,000
DEUTSCHE BANK AG\ 0.53% 317,335 +0.83% 0% $1,643,795
GOLDMAN SACHS GROUP INC 0.51% 305,706 +67% 0% $1,583,557
JANE STREET GROUP, LLC 0.51% 303,852 +21% 0% $1,573,954
TWO SIGMA INVESTMENTS, LP 0.48% 287,364 +5.2% 0% $1,488,546
WOODSTOCK CORP 0.45% 266,756 0% 0.12% $1,381,796

Institutional Holders of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 38,929,706 $201,592,852 -$2,790,250 $5.18 134
2025 Q3 39,235,813 $204,754,194 +$26,942,510 $5.22 130
2025 Q2 34,234,495 $131,165,420 -$14,803,182 $3.83 121
2025 Q1 37,522,553 $215,581,662 +$3,357,660 $5.75 124
2024 Q4 37,181,780 $185,566,183 +$2,534,433 $4.99 117
2024 Q3 36,411,204 $196,355,871 +$6,362,230 $5.39 111
2024 Q2 35,332,656 $116,899,840 -$329,270 $3.31 103
2024 Q1 35,411,236 $115,798,928 +$808,753 $3.27 101
2023 Q4 35,121,957 $123,276,317 -$16,780,776 $3.51 103
2023 Q3 37,775,090 $252,308,601 -$9,900,512 $6.68 120
2023 Q2 39,037,773 $327,514,881 +$24,184,461 $8.39 119
2023 Q1 35,585,837 $353,348,951 +$15,344,761 $9.93 107
2022 Q4 34,171,691 $237,833,495 -$18,830,170 $6.96 93
2022 Q3 36,966,565 $197,399,795 +$1,459,079 $5.34 85
2022 Q2 36,943,694 $147,408,805 -$7,357,330 $3.99 88
2022 Q1 38,636,557 $171,807,935 +$10,287,580 $4.44 102
2021 Q4 36,272,402 $145,130,796 -$44,887,818 $4.00 110
2021 Q3 39,720,964 $348,695,759 -$60,891,971 $8.78 114
2021 Q2 45,258,901 $512,794,552 +$153,473,538 $11.33 130
2021 Q1 31,692,851 $376,513,639 +$122,609,589 $11.88 107
2020 Q4 22,091,649 $151,541,784 -$10,169,396 $6.86 95
2020 Q3 23,807,765 $176,308,405 +$68,333,848 $7.41 84
2020 Q2 14,645,367 $61,066,116 -$6,590,170 $4.17 79
2020 Q1 16,769,610 $41,415,535 -$6,410,268 $2.47 69
2019 Q4 17,701,121 $102,840,148 +$1,433,085 $5.81 76
2019 Q3 16,864,477 $88,888,097 -$685,228 $5.27 70
2019 Q2 16,888,317 $101,327,468 +$1,168,639 $6.00 75
2019 Q1 16,361,337 $147,746,642 -$6,160,793 $9.03 77
2018 Q4 17,157,946 $141,481,000 -$15,993,709 $8.30 75
2018 Q3 18,046,261 $248,653,190 +$81,737,278 $13.80 90
2018 Q2 12,131,183 $96,444,142 +$14,632,796 $7.95 65
2018 Q1 10,285,308 $77,138,000 +$3,821,299 $7.50 42
2017 Q4 9,777,889 $66,488,000 +$3,712,599 $6.80 35
2017 Q3 9,221,517 $66,394,000 +$13,267,111 $7.20 35
2017 Q2 7,437,286 $34,736,000 -$2,554,099 $4.65 24
2017 Q1 7,897,813 $37,958,000 +$8,366,763 $5.00 24
2016 Q4 6,136,618 $32,831,000 +$111,606 $5.35 20
2016 Q3 6,112,780 $47,882,100 -$1,304,703 $7.82 22
2016 Q2 6,358,443 $36,177,450 +$11,374,826 $5.69 25
2016 Q1 4,372,667 $18,317,243 -$231,292 $4.19 26
2015 Q4 4,427,755 $30,018,000 +$376,484 $6.78 20
2015 Q3 4,330,050 $25,241,000 +$608,221 $5.83 22
2015 Q2 4,225,512 $32,853,000 +$19,634,402 $7.76 23
2015 Q1 1,691,795 $17,415,000 +$8,386,368 $10.18 15
2014 Q4 870,129 $6,277,000 +$82,000 $7.18 5
2014 Q3 859,337 $5,163,000 +$34,237 $5.74 6
2014 Q2 852,047 $5,639,000 +$5,638,000 $6.56 5